This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Gounaris, I. Articles by Ahmad, A. PubMed PubMed Citation Articles by Gounaris, I. Articles by Ahmad, A. Social Bookmarking                         What's this?

Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer

¹ Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital
² Queen Elizabeth Hospital

^* To whom correspondence should be addressed. E-mail: ioannis.gounaris{at}addenbrookes.nhs.uk.

	Abstract

Introduction. Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity. The neurologic toxicity of 5-fluorouracil, the original fluoropyrimidine, including an ataxic cerebellar syndrome is well described. However, only a few case reports exist describing a similar syndrome associated with capecitabine administration.

Case Report. We report a case of reversible cerebellar toxicity during chemotherapy with a combination of capecitabine and oxaliplatin.

Discussion. Rare fluoropyrimide-related toxicities are increasingly being reported in association with capecitabine. Clinical vigilance is required to ensure appropriate investigation and treatment.

First published on October 15, 2009
Journal of Oncology Pharmacy Practice 2009, doi:10.1177/1078155209349201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?